Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

A stake by France-owned Bpifrance and promise of local job retention have allayed political backlash over the sale of ...

Jobs — and national identity — top French concerns over the news that pharmaceutical company Sanofi plans to sell 50% of ...

Sanofi is in discussions with the French government to address concerns officials raised about a potential sale of a ...

Sanofi, which is joining a growing number of drugmakers shedding consumer related businesses, said Opella had been valued at ...

France will take a stake in Sanofi's Opella through the Public Investment Bank (BPI), finance minister Antoine Armand said on ...

Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Sanofi and private equity firm CD&R are in negotiations to sell a 50% stake in Opella, Sanofi's consumer healthcare division.

Earlier this month, Sanofi revealed talks were ongoing with CD&R, and has now confirmed the negotiations could result in the ...

Sanofi and CD&R have entered exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant ...